DSS, INC. (DSS): Nasdaq/NYSE listing notice — DSS receives NYSE American low-price delisting notice; must cure by Apr 20, 2024

DSS, INC.

Received letter from NYSE American on Oct 20, 2023, citing low share price for substantial period.
Continued listing conditioned on reverse stock split or sustained price improvement by Apr 20, 2024.
Exchange may take accelerated delisting if shares trade at abnormally low levels.
DSS intends to cure deficiency and return to compliance; stock will trade with .BC notation.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

DSS, INC. received a nyse_american deficiency notice notice regarding other (rules 1003(f)(v)).

Exchange: nyse american
Notice: deficiency notice
Rules: 1003(f)(v)

Exact text from the filing

October 20, 2023, DSS, Inc. (the “Company”) received a letter (the “Letter”) from the staff of NYSE American LLC (the “Exchange”) stating that the Company’s securities have been selling for a low price per share for a substantial period of time and, pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the Company’s continued listing is predicated on it effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which the Exchange has determined to be no later than April 20, 2024. However, the Excha

View on SEC.gov

Browse all listing & compliance notices →

DSS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-038426

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.